The total number of records retrieved from this search are 25. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_1451	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineHOP-92	Concentration of cell lineNA	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentrationLog10 pfu/cell	In-vitro result30% cell survived 48 hours after post infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1454	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with palcitaxel (38.50 +/- 16.01 micromolar, 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineHOP-92	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result50% cell death occurs at 0.144 CI value	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1460	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with palcitaxel (38.50 +/- 16.01 micromolar, 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineHOP-92	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result75% cell death at CI value 0.295	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1466	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with palcitaxel (38.50 +/- 16.01 micromolar, 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineHOP-92	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result90% cell death at CI value 0.613	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1472	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with palcitaxel (38.50 +/- 16.01 micromolar, 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineHOP-92	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result50% cell death occurs at 0.178 CI value	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1478	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with palcitaxel (38.50 +/- 16.01 micromolar, 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineHOP-92	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result75% cell death at CI value 0.420	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1484	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with palcitaxel (38.50 +/- 16.01 micromolar, 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineHOP-92	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result90% cell death at CI value 0.994	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1490	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with cisplatin (6.82+/- 3.22, ratio is 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineHOP-92	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result50% cell death at CI value 0.352	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1496	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with cisplatin (6.82+/- 3.22, ratio is 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineHOP-92	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result75% death at CI value 0.325	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1502	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with cisplatin (6.82+/- 3.22, ratio is 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineHOP-92	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result90% cell death at CI value 0.500	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1508	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with cisplatin (6.82+/- 3.22, ratio is 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineHOP-92	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result50% cell death at CI value 0.053	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1514	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with cisplatin (6.82+/- 3.22, ratio is 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineHOP-92	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result75% death at CI value 0.099	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1520	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with cisplatin (6.82+/- 3.22, ratio is 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineHOP-92	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result90% cell death at CI value 0.195	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1526	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Gemcitabine (0.83+/- 0.61, 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineHOP-92	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result50% cell death at CI value 0.372	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1532	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Gemcitabine (0.83+/- 0.61, 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineHOP-92	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result75 % cell death at CI 0.117	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1538	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Gemcitabine (0.83+/- 0.61, 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineHOP-92	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result90% cell killing at CI 0.047	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1544	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Gemcitabine (0.83+/- 0.61, 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineHOP-92	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result50% cell killing at CI 0.099	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1550	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Gemcitabine (0.83+/- 0.61, 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineHOP-92	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result75% cell killing at CI 0.110	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1556	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Gemcitabine (0.83+/- 0.61, 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineHOP-92	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result90% cell killing at CI 0.127	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1562	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with vinblastine(48.40+/-23.08, 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineHOP-92	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result50% cell killing at CI 1.749	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1568	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with vinblastine(48.40+/-23.08, 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineHOP-92	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result75% cell killing at CI 7.049	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1574	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with vinblastine(48.40+/-23.08, 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineHOP-92	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result90% cell killing at CI >10	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1580	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with vinblastine(48.40+/-23.08, 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineHOP-92	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result50% cell killing at CI 0.133	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1586	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with vinblastine(48.40+/-23.08, 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineHOP-92	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result75% cell killing at CI 1.256	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1592	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with vinblastine(48.40+/-23.08, 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineHOP-92	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result90% cell killing at CI 11.922	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950